Market Research Logo

Alzheimer's Disease: Selections from "The World Market for Neurotherapeutic Drugs"

This report on Alzheimer’s disease represents selections from the larger market research study on neurotherapeutic drugs published by Kalorama Information in August 2002. The full study looked at the entire range of non-psychiatric neurological diseases and their treatments in the top seven world health markets. Here we present those parts of that study that are germane to Alzheimer’s disease.

In addition to the relevant selections, which are indicated on the Table of Contents and List of Exhibits in bold face with page numbers, we have also included the following in this report:

  • The complete Executive Summary from the full study;
  • Discussion of promising cutting-edge technologies and treatments with potentially broad application not limited to Alzheimer’s;
  • Top-level market numbers on the total worldwide market for neurotherapeutic drugs;
  • The Conclusions and Strategic Implications from the full study;
  • Appendix A: Glossary of Terms; and
  • Appendix B: Company Directory


Alzheimer’s: Selections from "The World Market for Neurotherapeutic Drugs"

In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resultant report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of the real drivers of this market—are more focused on individual neurological disorders such as multiple sclerosis, Alzheimer’s disease, or neurological cancers, rather than the broad therapeutic category as a whole.

Therefore, Kalorama is now offering selections from the neurotherapeutics study, covering each of these topics in turn, while at the same time providing selected overall findings in other disease areas to allow for comparison and context. The selections provide the study’s full results in the specific area and the general context and strategic implications from the full study, all at a fraction of the cost.

Among the selections, you’ll find:

I. Executive Summary (15 pages) —Included in this selection is the complete executive summary from the full neurotherapeutics report, providing you with an overview of the entire neurotherapeutics market and top-level numbers on such neurological diseases as peripheral neuropathy, Parkinson’s disease, and Alzheimer’s disease, among others for the top seven world markets. The executive summary outlines the context of the entire neurology market and how MS therapeutics fit in.

II. Introduction (2 pages) —Selection includes the overview of Alzheimer’s disease, including prevalence estimates.

III. Treatment (10 pages) —This selection reviews current treatment protocols and the agents used in Alzheimer’s, including antipsychotics, anxiolytics, antidepressants, and anticonvulsants

IV. Progress and Promise in Therapeutic Development (31 pages) —Because progress on other neurotherapeutic fronts can have significant impact on Alzheimer therapeutics, information about all of the developments in neurogenomics and neural implants that the full study covered are included in this selection. Information specific to Alzheimer’s disease includes Table 4-2: Active Clinical Trials Involving Alzheimer’s Disease.

V. World Market Analysis (28 pages, including 10 tables and 4 figures) —Selection provides complete market projections and growth rates for Alzheimer’s therapeutics in each of the top world markets. Growth rates for Alzheimer’s markets and those of other major neurological diseases are included, along with total world numbers for comparison.

VI. Company Profiles (104 pages) —Profiles of the following companies are included:

  • Axonyx
  • Boston Life Sciences, Inc.
  • Centaur Pharmaceuticals, Inc.
  • Cephalon, Inc. Cortex Pharmaceuticals, Inc.
  • D-Pharm Ltd.
  • Elan Corporation plc
  • Guilford Pharmaceuticals Inc.
  • MitoKor Inc.
  • NeoTherapeutics, Inc.
  • NPS Pharmaceuticals, Inc.
  • Neurobiological Technologies, Inc.
  • Neurochem, Inc.
  • Neurocrine BioSciences, Inc.
  • Neurogen, Inc.
  • Shire Pharmaceuticals Group plc
  • Stem Cells Inc.
  • Titan Pharmaceuticals, Inc.

VII. Conclusions and Strategic Implications (9 pages) —This selection represents all of the analyst’s conclusions from the neurotherapeutics study as a whole, spelling out seven main conclusions and what they mean for developers and marketers of neurotherapeutic agents.

VIII. Glossary (8 pages)

IX. Company Directory (8 pages)

Executive Summary

  • Background
  • Scope and Methodology
  • Size and Growth of Market
  • Market Trends

Overview of Neurologic Diseases and Disorders

  • Key Neurologic Diseases and Disorders
  • Alzheimer’s Disease

Treatment of Neurologic Diseases and Disorders

  • Alzheimer’s Disease
  • Antipsychotics
  • Anxiolytics
  • Antidepressants
  • Anticonvulsants

Progress and Promise in Therapeutics Development

  • Genetics and Neurogenomics
  • Neural Implant Technologies
  • Miscellaneous Advances
  • Vascular Endothelial Growth Factor (VEGF
  • Minocycline
  • Stroke and Apoptosis
  • Clinical Trial Activity

World Market Analysis

  • Background
  • The Markets by Geography
  • The United States
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • The Market by Applications
  • Alzheimer’s Disease and Other Dementias

Company Profiles

  • Axonyx
  • Boston Life Sciences, Inc.
  • Centaur Pharmaceuticals, Inc.
  • Cephalon, Inc. Cortex Pharmaceuticals, Inc.
  • D-Pharm Ltd.
  • Elan Corporation plc
  • Guilford Pharmaceuticals Inc.
  • MitoKor Inc.
  • NeoTherapeutics, Inc.
  • NPS Pharmaceuticals, Inc.
  • Neurobiological Technologies, Inc.
  • Neurochem, Inc.
  • Neurocrine BioSciences, Inc.
  • Neurogen, Inc.
  • Shire Pharmaceuticals Group plc
  • Stem Cells Inc.
  • Titan Pharmaceuticals, Inc.

Conclusions and Strategic Implications

  • First Conclusion
  • Second Conclusion
  • Third Conclusion
  • Fourth Conclusion
  • Fifth Conclusion
  • Sixth Conclusion
  • Seventh Conclusion

Glossary

Company Directory

List of Exhibits

  • Table 1-1: Estimated Market Sizes for the Top Five Applications Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
  • Table 1-2: Estimated Market Sizes for the Geographic Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
  • Table 4-1: Known Genetic Alternation in Neurologic Neoplasms
  • Table 4-2: Active Clinical Trials Involving Alzheimer’s Disease and Dementia
  • Table 5-1: The Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2001-2010
  • Table 5-2: The Potential for Neurotherapeutics in the United States by Application, 2001-2010
  • Table 5-3: The Potential for Neurotherapeutics in France by Application, 2001-2010
  • Table 5-4: The Potential for Neurotherapeutics in Germany by Application, 2001-2010
  • Table 5-5: The Potential for Neurotherapeutics in Italy by Application, 2001-2010
  • Table 5-6: The Potential for Neurotherapeutics in Spain by Application, 2001-2010
  • Table 5-7: The Potential for Neurotherapeutics in the United Kingdom by Application, 2001-2010
  • Table 5-8: The Potential for Neurotherapeutics in Japan by Application, 2001-2010
  • Table 5-9: The Potential for Neurotherapeutics in the Major World Healthcare Markets by Application 2001-2010
  • Table 5-10: The Potential for Alzheimer’s Disease/Dementia Therapeutics in the Major World Healthcare Markets 2001-2010
  • Figure 1-1: Incidence of Major Neurologic Diseases in the Major World Healthcare Markets, 2001-2010
  • Figure 1-2: The Total Market for Neurotherapeutics in the Major World Healthcare Markets, 2001-2010
  • Figure 1-3: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Application, 2001-2009
  • Figure 1-4: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Geographic Region, 2001-2009
  • Figure 1-5: Composition of the Markets for Neurotherapeutics by Applications Segment, 2002 and 2010
  • Figure 1-6: Composition of the Markets for Neurotherapeutics by Geographic Segment, 2002 and 2010
  • Figure 4-1: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 1-4
  • Figure 4-2: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 5-8
  • Figure 4-3: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 9-12
  • Figure 4-4: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 13-16
  • Figure 4-5: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 17-20
  • Figure 4-6: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 21, 22, X, and Y
  • Figure 5-1: Growth Rates in Neurotherapeutics Potential for the Seven Major World Healthcare Markets, 2001-2010
  • Figure 5-2: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2002
  • Figure 5-3: Growth Rates in Neurotherapeutics Market Opportunities 2001-2010
  • Figure 5-4: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets by Application, 2002

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report